OBJECTIVE: To determine the efficacy and tolerability of subcutaneous beta interferon 1b
(B1F1b) among Saudi patients with remitting-relapsing multiple sclerosis (RR MS) …

To determine the efficacy and tolerability of subcutaneous Interferon beta 1a [IFN beta-1a]
among Iraqi patients with relapsing remitting multiple sclerosis [RRMS]. The study was held …

Multiple sclerosis (MS) is an autoimmune neurodegenerative disease that affects the central
nervous system. It is the second cause of neurological disability in young adults. The exact …

Background Previous trials of interferon β in multiple sclerosis (MS) have shown efficacy, but
the degree of clinical benefit remains uncertain, and the optimum dose is not known. We …

The aim of the study was to analyze the usefulness and side effects of treatment with
interferon beta 1B (Betaferon) in patients with the relapsing-remitting form of multiple …

Background: Indian-Asian multiple sclerosis behaves somewhat differently from Western
disease. It is not known if the response to β-interferon is also different. Aim: To demonstrate …

The aim of the study was to evaluate the efficacy of interferon beta-1a (IFN-β-1a) and beta-
1b (IFN-β-1b) in clinical practice for the treatment of relapsing-remitting multiple sclerosis …

We report a multicenter, randomized, double-blind, placebo-controlled trial of interferon beta-
1b (IFNB) in 372 ambulatory patients with relapsing-remitting multiple sclerosis (MS). Entry …

Sažetak We present a randomized open-label study of interferon-beta-1a in 14 patients with
relapsing-remitting multiple sclerosis. Interferon-beta-1a was administred in dose of 11 mg …

We report a multicenter, randomized, double-blind, placebo-controlled trial of interferon beta-
lb (IFNB) in 372 ambulatory patients with relapsing-remitting multiple sclerosis (MS). Entry …